A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients with Clinical or Laboratory Tumor Lysis Syndrome

Conclusions In this analysis of TLS patients receiving care in real-world settings, rasburicase vs allopurinol was significantly more effective in treating hyperuricemia and was associated with significantly shorter ICU and overall hospital stays and lower total inpatient costs. Teaser Management of tumor lysis syndrome (TLS), a potentially fatal oncologic complication following initiation of chemotherapy or other cytotoxic treatment or occurring spontaneously before treatment, has significant economic impact. This retrospective study of hospital administrative data from pediatric and adult patients with laboratory or clinical TLS found that patients treated with rasburicase, compared with those receiving allopurinol, had significantly greater mean reduction in UA levels, significantly lower ICU and overall hospital length of stay, and lower total hospitalization costs.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research